Correlation Between Axsome Therapeutics and Protalix Biotherapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Axsome Therapeutics and Protalix Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Axsome Therapeutics and Protalix Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Axsome Therapeutics and Protalix Biotherapeutics, you can compare the effects of market volatilities on Axsome Therapeutics and Protalix Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Axsome Therapeutics with a short position of Protalix Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Axsome Therapeutics and Protalix Biotherapeutics.

Diversification Opportunities for Axsome Therapeutics and Protalix Biotherapeutics

0.4
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Axsome and Protalix is 0.4. Overlapping area represents the amount of risk that can be diversified away by holding Axsome Therapeutics and Protalix Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Protalix Biotherapeutics and Axsome Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Axsome Therapeutics are associated (or correlated) with Protalix Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Protalix Biotherapeutics has no effect on the direction of Axsome Therapeutics i.e., Axsome Therapeutics and Protalix Biotherapeutics go up and down completely randomly.

Pair Corralation between Axsome Therapeutics and Protalix Biotherapeutics

Given the investment horizon of 90 days Axsome Therapeutics is expected to under-perform the Protalix Biotherapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Axsome Therapeutics is 1.01 times less risky than Protalix Biotherapeutics. The stock trades about -0.38 of its potential returns per unit of risk. The Protalix Biotherapeutics is currently generating about 0.35 of returns per unit of risk over similar time horizon. If you would invest  163.00  in Protalix Biotherapeutics on October 5, 2024 and sell it today you would earn a total of  25.00  from holding Protalix Biotherapeutics or generate 15.34% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Axsome Therapeutics  vs.  Protalix Biotherapeutics

 Performance 
       Timeline  
Axsome Therapeutics 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Very Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Axsome Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of very healthy basic indicators, Axsome Therapeutics is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors.
Protalix Biotherapeutics 

Risk-Adjusted Performance

20 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Protalix Biotherapeutics are ranked lower than 20 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain essential indicators, Protalix Biotherapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Axsome Therapeutics and Protalix Biotherapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Axsome Therapeutics and Protalix Biotherapeutics

The main advantage of trading using opposite Axsome Therapeutics and Protalix Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Axsome Therapeutics position performs unexpectedly, Protalix Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Protalix Biotherapeutics will offset losses from the drop in Protalix Biotherapeutics' long position.
The idea behind Axsome Therapeutics and Protalix Biotherapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Other Complementary Tools

Transaction History
View history of all your transactions and understand their impact on performance
Equity Valuation
Check real value of public entities based on technical and fundamental data
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data